REPL News and Press, Replimune Group Inc. From 09/03/25

Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman PR Newswire SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback th...

2025-09-02 15:00:47 ET More on Replimune Group Replimune Group: The Prospects For FDA Approval After Rejection Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program Biotech sector slips amid reported return of ousted FDA official Biggest stock m...

WOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled t...

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - REPL PR Newswire NEW YORK , Aug. 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune G...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and Ju...

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, ...

New York, New York--(Newsfile Corp. - August 11, 2025) - If you suffered a loss on your Replimune Group, Inc. (NASDAQ: REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune...

2025-08-11 06:25:01 ET More on Sarepta Therapeutics, Capricor Therapeutics, Inc., etc. Replimune Group: The Prospects For FDA Approval After Rejection Sarepta Therapeutics: Beaten Down, But Not Out Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program ...

Replimune Group Inc. (REPL) is expected to report $-0.83 for Q1 2026

2025-08-07 10:43:47 ET More on Replimune Group Replimune Group: The Prospects For FDA Approval After Rejection Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript Replimune down as ...